European urology · 2011
The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature.
СтатьяПоддержка исследования: вне правительства СШАОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sonpavde Guru, Attard Gerhardt, Bellmunt Joaquim, Mason Malcolm D, Malavaud Bernard, Tombal Bertrand, Sternberg Cora N
Аннотация
CONTEXT: The development of agents targeting androgen signalling holds promise for men with castration-resistant prostate cancer (CRPC).
OBJECTIVE: The emerging role of abiraterone acetate (AA), a novel, orally administered androgen synthesis inhibitor, is critically analysed.
EVIDENCE ACQUISITION: Data were acquired from critically important original research published in peer-reviewed literature or presented at conferences conducted by the American Society of Clinical Oncology and the European Society of Medical Oncology.
EVIDENCE SYNTHESIS: The major findings are addressed in an evidence-based, objective, and balanced fashion.
CONCLUSIONS: AA specifically inhibits CYP17 and substantially reduces serum androgen levels without inducing significant adrenal insufficiency. A phase 3 trial reported a significant extension of survival in metastatic CRPC with AA plus prednisone compared to prednisone alone following docetaxel. The primary toxicity of mineralocorticoid excess is manageable. The addition of low-dose corticosteroids to AA may be necessary for controlling symptoms of mineralocorticoid excess.
OBJECTIVE: The emerging role of abiraterone acetate (AA), a novel, orally administered androgen synthesis inhibitor, is critically analysed.
EVIDENCE ACQUISITION: Data were acquired from critically important original research published in peer-reviewed literature or presented at conferences conducted by the American Society of Clinical Oncology and the European Society of Medical Oncology.
EVIDENCE SYNTHESIS: The major findings are addressed in an evidence-based, objective, and balanced fashion.
CONCLUSIONS: AA specifically inhibits CYP17 and substantially reduces serum androgen levels without inducing significant adrenal insufficiency. A phase 3 trial reported a significant extension of survival in metastatic CRPC with AA plus prednisone compared to prednisone alone following docetaxel. The primary toxicity of mineralocorticoid excess is manageable. The addition of low-dose corticosteroids to AA may be necessary for controlling symptoms of mineralocorticoid excess.